Panacea Acquisition today filed an investor presentration on merger partner Nuvation Bio, which is focused on developing cancer treatments. The deal was announced in October.
In addition to the approximately $144 million held in Panacea’s trust (assuming no redemptions), a group of premier healthcare investors has committed to participate in concurrent equity financings totaling slightly more than $500 million at $10 per share. Read more.
Related Posts
SCHMID GROUP Combining with Pegasus Digital Mobility Acquisition in $640M Deal
The target is a global solutions provider for the high-tech electronic, photovoltaics, glass, and energy systems industries.
Astrea Acquisition Files Prelim Proxy on mergers with HotelPlanner and Reservations.com
The transaction is expected to provide HotelPlanner with more than $120 million in cash proceeds.
FTAC Zeus Acquisition Lowers Deal Size 32% Ahead of $300M IPO
FTAC is targeting companies engaged in fintech.
Northern Star Investment III, IV Secure Additional NRAs
Each SPAC raised $350 million in March 2021 IPOs, although redemptions have cut deeply into the trusts of both since then.